It seems we have already hit the panic button less than one month in.
-
Thurs news: Lilly’s weight-loss drug prevents diabetes. Merck pays $588M for bispecific. Amgen speaks out about bone density issues with obesity drug. PTC gets gene therapy approval. JNJ’s 340B legal fight. See more on our front page
So what you are saying is it did $14 million in it's first month. Wow. No wonder the reps aren't gonna make any $.
1,000 TRx filled (not 1200 estimate by lying rick) in a month including paid prescriptions and bridge access program is weak. Based on this volume, RIN captured a pitiful 5% of in-play RA patients? Barely beating the dog Remicade? Yeah you’ll make a dent in Humira loss, NOT!
Then why does the stock price continue to climb? Are you judging the company future on one product? Moron!
Yup, this whole pipeline including rIn can’t negate the loss of Humira in three years.
The problem is it’s a jak. And the thought leaders believe a jak is a jak...with the exception of the Lilly jak in the US because the approved dose is to low. Compared vs humira they have a lot more regular testing they need to do. No one really cares that it’s an oral vs shot. Rinvoq is a good product but so are it’s competitors...I see peak sales 3 billion. Even with better access. Skyrizi a little less. Our goals are ridiculous.
Agreed that the goals are laughably absurd. Someone not only missed the mark, they missed the whole wall. Sales force is as demoralized as any I have ever seen, which says a lot. If you keep beating a dog to death, it's will eventually dies, it turns on you or it leaves. The Rinvoq reps are the dog in this scenario.
Rick was lying AGAIN on Q3ER call, "With the strong benefit-risk profile demonstrated across our registrational trials, Rinvoq offers meaningful advantages over products on the market today or in development for rheumatoid arthritis."...
The truth:
Recent ICER report stated NO marginal clinical benefit over Humira and cost is MORE. Report stated only modestly more effective than older RA drug.
This affected stock climb. Rick needs to be fired!
The truth:
Recent ICER report stated NO marginal clinical benefit over Humira and cost is MORE. Report stated only modestly more effective than older RA drug.
This affected stock climb. Rick needs to be fired!